Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929450 | 0.87 | ADRA2A (0.42) | ADRA2ATAAR1ADRA2BADRA2CADRA1D | |
| SCHEMBL7922106 | 0.79 | TAAR1 (0.34) | ADRA2ATAAR1 | |
| SCHEMBL14707611 | 0.79 | ADRA2A (0.37) | ADRA2ATAAR1ADRA2BADRA2CADRA1D | |
| SCHEMBL12203774 | 0.77 | ADRA2A (0.55) | ADRA2ATAAR1ADRA2BADRA2CADRA1D | |
| SCHEMBL14707610 | 0.75 | KDM4E (0.35) | — | |
| SCHEMBL7917546 | 0.74 | TAAR1 (0.72) | ADRA2ATAAR1ADRA2BADRA2CADRA1D | |
| SCHEMBL7929405 | 0.71 | ADRA2A (0.36) | ADRA2ATAAR1 | |
| SCHEMBL7918652 | 0.68 | ADRA2A (0.51) | ADRA2ATAAR1ADRA2BADRA2CADRA1D | |
| SCHEMBL7922771 | 0.68 | TAAR1 (0.33) | ADRA2ATAAR1 | |
| SCHEMBL7927693 | 0.68 | PRCP (0.42) | ADRA2ATAAR1ADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | ADRA2A 3/4885TAAR1 162/4885ADRA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.